- Home
- CHEF vs DNLI Comparison
CHEF vs DNLI Comparison
Compare CHEF & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHEF | DNLI |
|---|---|---|
| Founded | 1985 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.7B |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CHEF | DNLI |
|---|---|---|
| Price | $95.70 | $25.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $76.33 | $34.33 |
| AVG Volume (30 Days) | 540.1K | ★ 2.0M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $1,301,520,000.00 | N/A |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $7.83 | $408.85 |
| P/E Ratio | $239.05 | ★ N/A |
| Revenue Growth | ★ 9.11 | N/A |
| 52 Week Low | $53.24 | $12.58 |
| 52 Week High | $97.63 | $26.80 |
Technical Indicators
Market Signals| Indicator | CHEF | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 70.60 | 74.24 |
| Support Level | $57.47 | $18.07 |
| Resistance Level | $97.63 | N/A |
| Average True Range (ATR) | 3.06 | 1.15 |
| MACD | -0.15 | 0.24 |
| Stochastic Oscillator | 75.05 | 83.50 |
Price Performance
Historical ComparisonAbout CHEF The Chefs' Warehouse Inc.
The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States, the Middle East and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.